Latest Breaking News On - Joycef liu - Page 1 : comparemela.com

Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition

Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.

United statesDana farber cancer instituteSri lankaJoycef liuEnd results programZentalis pharmaceuticalsWomen healthHarvard medical schoolDivision of gynecologic oncologyAmerican society of clinical oncology annual meetingNational cancer institute surveillanceGynecologic oncologyDisplays preliminary efficacyClinical oncology annual meetingGynecologic oncology annual meetingCancer institute surveillance

Dr Liu on the Rationale for Targeting Wee1 in Ovarian Cancer

Dr Liu on the Rationale for Targeting Wee1 in Ovarian Cancer
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Joycef liuHarvard medical schoolDana farber cancer instituteDivision of gynecologic oncologyGynecologic oncology

Moore Details Ongoing Research Aiming to Fill Unmet Needs in Ovarian Cancer

Kathleen N. Moore, MD, MS, expands on the importance of continuing to investigate PARP inhibitors in ovarian cancer and highlights key updates to have come out of the 2023 ESMO Congress

United statesUniversity of oklahomaOklahoma cityDana farber cancer instituteJoycef liuKathleenn mooreFloortjej backesShannonn westinUniversity of oklahoma health stephenson cancer centerUniversity of texas md anderson cancer centerOhio state university comprehensive cancer centerEuropean medicines agencyPhasei programStephenson cancer centerClinical researchUniversity of oklahoma college medicine

Ovarian cancer research at ESMO Congress explores chemotherapy-free treatment options

Ovarian cancer research at ESMO Congress explores chemotherapy-free treatment options
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Min leeKosei hasegawaByerin michaelMindy valcarcelJoycef liuLasker clinical research scholarCancer researchEuropean society for medical oncology congressWomen malignancies branchSaitama medical university international centerDana farber cancer instituteMalignancies branchEuropean societyMedical oncology congress

Olaparib Does Not Improve OS vs Chemo in Recurrent Platinum-Sensitive Ovarian Cancer

The use of olaparib as a monotherapy or in combination with cediranib did not provide a statistically significance overall survival (OS) benefit compared with standard of care platinum-based chemotherapy in patients with recurrent, platinum-sensitive ovarian cancer.

Joycef liuHarvard medical schoolClinical researchDivision of gynecologic oncologyDana farber cancer instituteClinical research programGynecologic oncologyHarvard medicalOvarian cancer